The patients underwent PET with 18F-labeled PSMA ligands, aiming to determine whether there was evidence of progressive prostate cancer, whereas imaging test identified no increased metabolic activity in prostate cancer post-operative area; meanwhile, the mean SUV of the bone and pancreas lesion reported was slightly high which were 4.9 and 7.5, respectively. Here, FOLH1 is linked to prostate cancer.